IMRX logo

IMMUNEERING CORP - CLASS A

IMRXNASDAQ
🏆 #3392 by market capUS Equity
$4.00—
Last available close · quote unavailable
🔔
Track IMRX
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▲ 5.0%
14d▲ 9.6%
30d▼ 3.1%
ytd▼ 39.1%
1y▼ 36.1%
🏦Market Cap
$258M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
28.0%
Moderate
💵FCF Margin
—
⚖️P/S Ratio
495.6x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$3.38 – $8.48
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
64.7M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
495.6x
EPS (TTM)
$-1.03
Dividend Yield
—
Dilution (1yr)
+108.0%
IMRX logo

IMMUNEERING CORP - CLASS A

IMRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
50.1%▲ +12.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$59M▼ −7.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$45M▼ −17.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64.6M▲ +108.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$125M▲ +$93M YoY
StockOtter · stockotter.space

About IMMUNEERING CORP - CLASS A

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.